Geospatial Disparities in Federal COVID-19 Test-to-Treat Program
Emily R. Smith, Erin Oakley
Abstract
Ritonavir-boosted nirmatrelvir (Paxlovid) is an antiviral drug indicated for the treatment of coronavirus disease 2019 (COVID-19) among nonhospitalized adults and children aged ≥12 years at high risk of disease progression. In the original trial, Paxlovid reduced the risk of hospitalization or death by 88% among high-risk, unvaccinated adults.1
Topics & Concepts
Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Geospatial analysisTest (biology)BetacoronavirusMEDLINECoronavirus InfectionsMedicineEnvironmental healthVirologyGeographyPolitical scienceRemote sensingPathologyPaleontologyOutbreakLawInfectious disease (medical specialty)DiseaseBiologyData-Driven Disease SurveillanceHealth, Environment, Cognitive AgingSARS-CoV-2 detection and testing